Last reviewed · How we verify

NCT07526987: EMPHASIS-2

Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis

Not yet recruiting Phase 3 Last updated 17 April 2026
What this trial tests

Phase 3 trial testing Minocycline Hydrochloride Capsule (50 mg per capsule) in Ischaemic Stroke in 934 participants. Not yet recruiting.

Timeline
1 May 2026
Primary endpoint
31 December 2028
31 December 2028

Quick facts

Lead sponsorBeijing Tiantan Hospital
PhasePhase 3
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment934
Start date1 May 2026
Primary completion31 December 2028
Estimated completion31 December 2028
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 18 to 80, any sex, with Ischaemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to assess the efficacy and safety of minocycline in improving functional outcome among patients with acute ischaemic stroke receiving intravenous thrombolysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ischaemic Stroke

Currently open trials in the same condition.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07526987.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing